The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.

World Healthcare Fund (THW) has a high 11.7% dividend yield, ideal for income generation and positioned for future growth in ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Looking for the best Charles Schwab mutual funds to add to your portfolio? See this list of the best funds to buy now.

CFO to depart at year-end in move that comes after CEO exited in September WW International Inc., the company known as ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report) and keeping the price target at $362.00.Don't ...

The stock's early-sessions lows when it was down more than 10 ... That news sent the stocks of market leaders Novo Nordisk A/S (NVO) and Eli Lilly & Co. (LLY) higher, along with Viking Therapeutics ...

NEW YORK (Reuters) - The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate ...

Investors are assessing the likelihood Trump will deliver on his threat to impose fresh tariffs on China, Canada and Mexico.